Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2016

Dec 24, 2016

30936_dirs_2016-12-23_25decbab-2f8f-4f8c-b1e3-f383cbd2dd95.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-24

Reporting Person: Versant Venture Capital IV, L.P. (10% Owner)
Reporting Person: Versant Side Fund IV, L.P. (10% Owner)
Reporting Person: Versant Venture Capital V, L.P. (10% Owner)
Reporting Person: Versant Affiliates Fund V, L.P. (10% Owner)
Reporting Person: Versant Ophthalmic Affiliates I, L.P. (10% Owner)
Reporting Person: Versant Venture Capital V (Canada), LP (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-10-24 Common Stock C 437247 Acquired 676895 Indirect
2016-10-24 Common Stock C 3100477 Acquired 3777372 Indirect
2016-10-24 Common Stock C 231077 Acquired 4008449 Indirect
2016-10-24 Common Stock P 95596 $14.00 Acquired 4104045 Indirect
2016-10-24 Common Stock C 2754 Acquired 2754 Indirect
2016-10-24 Common Stock C 19524 Acquired 22278 Indirect
2016-10-24 Common Stock C 1454 Acquired 23732 Indirect
2016-10-24 Common Stock P 602 $14.00 Acquired 24334 Indirect
2016-10-24 Common Stock C 2210417 Acquired 2210417 Indirect
2016-10-24 Common Stock C 173167 Acquired 2383584 Indirect
2016-10-24 Common Stock P 60219 $14.00 Acquired 2443803 Indirect
2016-10-24 Common Stock C 66490 Acquired 66490 Indirect
2016-10-24 Common Stock C 5210 Acquired 71700 Indirect
2016-10-24 Common Stock C 168224 Acquired 168224 Indirect
2016-10-24 Common Stock C 13180 Acquired 181404 Indirect
2016-10-24 Common Stock P 4583 $14.00 Acquired 185987 Indirect
2016-10-24 Common Stock C 73704 Acquired 73704 Indirect
2016-10-24 Common Stock C 5774 Acquired 79478 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-10-24 Series A-1 Preferred Shares $ C 437247 Disposed Common Stock (437247) Indirect
2016-10-24 Series A-1 Preferred Shares $ C 2754 Disposed Common Stock (2754) Indirect
2016-10-24 Series A-2 Preferred Shares $ C 3100477 Disposed Common Stock (3100477) Indirect
2016-10-24 Series A-2 Preferred Shares $ C 19524 Disposed Common Stock (19524) Indirect
2016-10-24 Series A-3 Preferred Shares $ C 2210417 Disposed Common Stock (2210417) Indirect
2016-10-24 Series A-3 Preferred Shares $ C 66490 Disposed Common Stock (66490) Indirect
2016-10-24 Series A-3 Preferred Shares $ C 168224 Disposed Common Stock (168224) Indirect
2016-10-24 Series A-3 Preferred Shares $ C 73704 Disposed Common Stock (73704) Indirect
2016-10-24 Series B Preferred Shares $ C 231077 Disposed Common Stock (231077) Indirect
2016-10-24 Series B Preferred Shares $ C 1454 Disposed Common Stock (1454) Indirect
2016-10-24 Series B Preferred Shares $ C 173167 Disposed Common Stock (173167) Indirect
2016-10-24 Series B Preferred Shares $ C 5210 Disposed Common Stock (5210) Indirect
2016-10-24 Series B Preferred Shares $ C 13180 Disposed Common Stock (13180) Indirect
2016-10-24 Series B Preferred Shares $ C 5774 Disposed Common Stock (5774) Indirect

Footnotes

F1: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016.

F2: These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interests therein.

F3: These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interests therein.

F4: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interests therein.

F5: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interests therein.

F6: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their pecuniary interests therein.

F7: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interests therein.